258 related articles for article (PubMed ID: 16628140)
1. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
[TBL] [Abstract][Full Text] [Related]
2. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
3. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
6. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
[TBL] [Abstract][Full Text] [Related]
7. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
8. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E; Nafziger AN; Kazierad DJ; Bertino JS
Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
[TBL] [Abstract][Full Text] [Related]
9. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
10. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
12. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.
Zhao P; Ragueneau-Majlessi I; Zhang L; Strong JM; Reynolds KS; Levy RH; Thummel KE; Huang SM
J Clin Pharmacol; 2009 Mar; 49(3):351-9. PubMed ID: 19246732
[TBL] [Abstract][Full Text] [Related]
13. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
14. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole.
Ziesenitz VC; König SK; Mahlke NS; Skopp G; Haefeli WE; Mikus G
J Clin Pharmacol; 2015 Jun; 55(6):708-17. PubMed ID: 25651378
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.
KuKanich B; Hubin M
J Vet Pharmacol Ther; 2010 Feb; 33(1):42-9. PubMed ID: 20444024
[TBL] [Abstract][Full Text] [Related]
17. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
Oo C; Chen YC
J Clin Pharmacol; 2009 Mar; 49(3):368-9; author reply 370. PubMed ID: 19246734
[No Abstract] [Full Text] [Related]
18. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
19. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
Stoch SA; Friedman E; Maes A; Yee K; Xu Y; Larson P; Fitzgerald M; Chodakewitz J; Wagner JA
J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
